Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00178841
Other study ID # 050416
Secondary ID
Status Completed
Phase Phase 2
First received September 12, 2005
Last updated January 20, 2016
Start date June 2005
Est. completion date March 2007

Study information

Verified date January 2016
Source Vanderbilt University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to determine if combination therapy with rosiglitazone and bexarotene might have a synergistic effect in the treatment of patients with CTCL.


Description:

Treatment options for CTCL include both skin-directed and systemic therapies. Topical treatments are effective for early-stage disease that is localized to the skin. However, disease involving the lymph nodes or visceral sites can be palliated but rarely cured, even with the most aggressive regimens of systemic chemotherapy. Unfortunately, current treatment options at this stage only provide a short term response. Thus, it is important that additional therapies are investigated to manage this malignancy.

Bexarotene has been approved by the FDA for the treatment of Cutaneous T-Cell Lymphoma (CTCL).Bexarotene binds the RXR(Retinoid X Receptor)inside the cell, a receptor that forms heterodimers with a multitude of other nuclear receptors. One of these is the PPARĪ³ (Peroxisome Proliferator Activator Receptor Gamma), a nuclear receptor that binds Rosiglitazone.Rosiglitazone is an FDA approved antidiabetic agent of the Thiazolidinedione class. Rosiglitazone increases insulin sensitivity and is useful in the treatment of type 2 diabetes. In vitro data suggest that rosiglitazone and bexarotene may act synergistically to induce apoptosis in cell lines derived from patients with cutaneous T cell lymphoma (CTCL). This pilot study will investigate this possible synergism in a small cohort of patients with stable or progressive CTCL already being treated with bexarotene.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date March 2007
Est. primary completion date March 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with biopsy proven persistent or recurrent cutaneous cell lymphoma (CTCL) Stage IA-IVA

- Patients with a pathologic proven diagnosis of CTCL that is documented in the patient history.

- Patient has preserved organ function.

- Patient has an ECOG performance status between 0 - 2.

- Women of childbearing potential should be screened for pregnancy prior to treatment and utilize effective contraceptive methods (e.g. barrier) during treatment period.

- Patients over the age of 18 who are willing and able to provide Informed Consent

- The patient has been taking Targretin capsules for at least the last 4 months and the dose has remained relatively stable.

- The patient has had stable or progressive disease over the past 4 months.

- Patient has adequate laboratory parameters for liver and kidney function.

Exclusion Criteria:

- Patients with CD30+ Anaplastic Large Cell Lymphoma

- Patients with pathology consistent with peripheral T-cell lymphoma.

- Patients with Stage IVB (visceral involvement with CTCL).

- Patients with history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C infection.

- Patients with a diagnosis of congestive heart failure.

- Patients exhibiting significant edema or unstable cardiovascular disease.

- Patients with a fasting triglyceride level greater then 500mg/dl.

- Patients that have started any new treatment for CTCL in the past 4 months.

- Pregnant women will be excluded from the study.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Rosiglitazone and Bexarotene
rosiglitazone added to bexarotene capsules

Locations

Country Name City State
United States Vanderbilt University Medical Center Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Vanderbilt University

Country where clinical trial is conducted

United States, 

References & Publications (11)

Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med. 1994 Oct 15;121(8):592-602. Review. — View Citation

Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep. 1979 Apr;63(4):725-8. — View Citation

Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA; Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004 Feb 7;363(9407):429-38. — View Citation

Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol. 2005 Mar;141(3):325-30. — View Citation

Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC; Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001 May 1;19(9):2456-71. — View Citation

Koh HK, Charif M, Weinstock MA. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct;9(5):943-60. Review. — View Citation

Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003 Jan;26(1):172-8. — View Citation

Shapiro PE. Advances in the histologic diagnosis of cutaneous T-cell lymphoma. Adv Dermatol. 1996;11:255-84; discussion 285. Review. — View Citation

Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004 Feb 1;93(3):362-5. — View Citation

Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Peréz JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, Santucci M, Smith N, Wechsler J, van Vloten WA, Meijer CJ. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997 Jul 1;90(1):354-71. Review. — View Citation

Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. J Invest Dermatol. 2004 Aug;123(2):380-7. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With a 50% Improvement in Baseline Skin Score mSWAT scoring. Range 0 to 400. Measured every 4 weeks. 16 weeks No
Secondary Quality of Life Evaluations FACT-G, Functional Assessment of Cancer Therapy-General (quality-of-life scale) 0= worst 108=best baseline and every 4 weeks No
Secondary Pruritus Score 10-cm visual analog scale, 10= worst, 1=best 16 weeks No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02881749 - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Completed NCT00051012 - Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Phase 4
Terminated NCT03789864 - Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides N/A
Completed NCT01590732 - Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Phase 1
Recruiting NCT02848274 - ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Recruiting NCT05357794 - Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides Phase 2
Completed NCT04955340 - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat Phase 1
Recruiting NCT04960618 - Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome Phase 2
Completed NCT02883517 - Cell-free Circulating DNA in Primary Cutaneous Lymphomas
Active, not recruiting NCT02953301 - Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) Phase 2
Completed NCT00254332 - Effect of Denileukin Diftitox on Immune System in CTCL Patients N/A
Completed NCT02296164 - Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Recruiting NCT05680558 - Photopheresis in Early-stage Mycosis Fungoides Phase 2
Completed NCT00038376 - Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Phase 2
Completed NCT00168064 - Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides Phase 2
Recruiting NCT05879458 - Ritlecitinib in CTCL Phase 2
Recruiting NCT05414500 - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Phase 1
Recruiting NCT05904522 - Histopathological Changes in Mycosis Fungoides N/A

External Links